Advertisement
U.S. markets open in 3 hours 43 minutes

Qiagen N.V. (QGEN)

NYSE - NYSE Delayed Price. Currency in USD
44.14+0.10 (+0.23%)
At close: 04:00PM EDT
43.98 -0.16 (-0.36%)
Pre-Market: 05:28AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close44.04
Open44.15
Bid0.00 x 800
Ask0.00 x 1000
Day's Range44.03 - 44.36
52 Week Range34.74 - 47.70
Volume593,003
Avg. Volume1,242,928
Market Cap9.771B
Beta (5Y Monthly)0.41
PE Ratio (TTM)28.85
EPS (TTM)1.53
Earnings DateMay 01, 2024 - May 06, 2024
Forward Dividend & Yield1.28 (2.94%)
Ex-Dividend DateJan 30, 2024
1y Target Est51.05
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
6% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for QGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Qiagen N.V.
    Analyst Report: Qiagen N.V.Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • GlobeNewswire

    QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

    Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers // Updated U.S. CDC guidelines mandate IGRA testing for individuals aged 2 and older from high‑TB incidence countries, as part of U.S. immigrant visa medical exam // QIAGEN to host global, CPD-accredited event on March 21, just before World TB Day, focusing on TB infection screening, preventive therapy and challenges of high-risk groupsGermantown, Maryland, and Venlo, the Netherlands,

  • Zacks

    Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?

    Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    QIAGEN announces Form 20-F annual report filing for 2023 results

    Venlo, the Netherlands, March 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will provide printed copies of the 2023 Annual Report to shareholders free of charge upon request. To obtain a p